{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:05:48Z","timestamp":1789362348370,"version":"build-2803163510"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Circulating tumour DNA (ctDNA), cell-free DNA (cfDNA) and urinary tumour DNA are increasingly studied in bladder cancer and urothelial carcinoma. We mapped the development, knowledge structure and clinical emphasis of this ctDNA\/cfDNA-centred literature and assessed its coverage across three bibliographic databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Web of Science Core Collection (WoSCC), Scopus and PubMed\/MEDLINE were searched on July 31, 2026, for records published in 2008-2025. Reviewer-expanded strategies included liquid biopsy, ctDNA\/cfDNA, molecular residual disease, molecular relapse, tumour-informed assays, urinary DNA, methylation, TERT and FGFR3. WoSCC was the primary mapping database; Scopus and PubMed\/MEDLINE were coverage comparators. Python, VOSviewer and CiteSpace were used for descriptive and network analyses. Newly retrieved WoSCC records underwent duplicate independent screening and full third-reviewer quality control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The searches retrieved 1,903 WoSCC, 3,201 Scopus and 230 PubMed\/MEDLINE records. After WoSCC deduplication and eligibility assessment, 494 records formed the main set and 698 formed a contextual set. The main set received 17,031 citations (median 19; interquartile range 7-42), and annual output reached 82 records in 2025. Scopus covered 456\/494 main records and PubMed\/MEDLINE covered 93\/494. Among 557 newly assessed records, the reviewers initially agreed on 433 (77.7%; Cohen\u2019s kappa, 0.620); all records then underwent third-reviewer full-text quality control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The expanded search identifies a larger DNA-focused literature than the original strategy and confirms unequal database coverage. Thematic clusters and citation bursts trace a shift from early methylation-marker research towards ctDNA-based molecular residual disease assessment and perioperative treatment stratification. Bibliometric prominence describes research activity, not diagnostic accuracy, predictive validity or treatment benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1906152","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:37:44Z","timestamp":1789360664000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["ctDNA- and cfDNA-based liquid biopsy in bladder cancer and urothelial carcinoma: bibliometric mapping and cross-database coverage analysis, 2008-2025"],"prefix":"10.3389","volume":"16","author":[{"given":"Junhua","family":"Li","sequence":"first","affiliation":[{"name":"Department of Urology, Hangzhou Third People\u2019s Hospital","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhao","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Urology, Hangzhou Third People\u2019s Hospital","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longfei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Hangzhou Third People\u2019s Hospital","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Urology, Hangzhou Third People\u2019s Hospital","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixian","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Urology, Hangzhou Third People\u2019s Hospital","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2023 guidelines","volume":"85","author":"Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human Malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158597","article-title":"A liquid biopsy in bladder cancer-the current landscape in urinary biomarkers","volume":"23","author":"Matuszczak","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and surveillance of bladder cancer using urine tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139597","article-title":"Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13148-022-01240-8","article-title":"Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation","volume":"14","author":"Hentschel","year":"2022","journal-title":"Clin Epigenet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.05.024","article-title":"Diagnostic test accuracy of urinary DNA methylation-based biomarkers for the detection of primary and recurrent bladder cancer: a systematic review and meta-analysis","volume":"10","author":"Silva-Ferreira","year":"2024","journal-title":"Eur Urol Focus"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12943-017-0644-5","article-title":"Liquid biopsy: a step forward towards precision medicine in urologic Malignancies","volume":"16","author":"Di Meo","year":"2017","journal-title":"Mol Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2025.13396","article-title":"New biomarkers for diagnosis of bladder cancer: a bibliometric analysis","volume":"97","author":"Falabella","year":"2025","journal-title":"Archivio Italiano di Urol e Andrologia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.90724","article-title":"Global research trends in bladder cancer biomarkers: a bibliometric analysis","volume":"17","author":"Zong","year":"2025","journal-title":"Cureus"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc For Inf Sci Technol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","article-title":"Genomic alterations in liquid biopsies from patients with bladder cancer","volume":"70","author":"Birkenkamp-Demtr\u00f6der","year":"2016","journal-title":"Eur Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.12.016","article-title":"Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer","volume":"71","author":"Christensen","year":"2017","journal-title":"Eur Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis","volume":"73","author":"Birkenkamp-Demtr\u00f6der","year":"2018","journal-title":"Eur Urol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1140","article-title":"Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer","volume":"23","author":"Vandekerkhove","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1767712","article-title":"Circulating tumor DNA as a prognostic and monitoring biomarker in urothelial cancers","volume":"16","author":"Aragon-Ching","year":"2026","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000001373","article-title":"Latest developments in urinary tumor DNA and its current clinical role in urothelial bladder cancer and upper tract urothelial carcinoma","volume":"36","author":"Gonz\u00e1lez-Padilla","year":"2026","journal-title":"Curr Opin Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1038\/s41467-026-69927-7","article-title":"Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer","volume":"17","author":"M\u00fcller","year":"2026","journal-title":"Nat Commun"},{"key":"B29","unstructured":"FDA approves atezolizumab for adjuvant treatment of muscle-invasive bladder cancer in patients who are ctDNA-MRD positive after radical cystectomy\n          \n          \n          \n          2026"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1906152\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:37:54Z","timestamp":1789360674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1906152\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":29,"alternative-id":["10.3389\/fonc.2026.1906152"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1906152","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1906152"}}